에 대한 최신 뉴스 Zoetis (NYSE:ZTS) 주식

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Zoetis Inc

Ztest Electronics Inc

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) appears to be <a href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt">turning a corner</a>. 
What Happened: Investor meetings hosted by William Blair this week gave analysts enough confidence to upgrade the stock, citing a stabilized core business and promising momentum in its innovation pipeline. With new product launches in both livestock and pet health, Elanco is better positioned for growth—though it still faces stiff competition from larger rivals like Zoetis and Merck.
Analyst Brandon Vazquez said meetings and conversations centered on current momentum <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and pipeline efforts</a>, giving the confidence to upgrade.
The analyst highlights that the core business (ex-innovation, or about 85% of sales) has stabilized due to improved execution or, bluntly, years of share losses that have made less competitive segments less impactful to the P&amp;L statement.
Also Read: <a href="https://www.benzinga.com/25/05/45257358/animal-health-elanco-sees-momentum-building-despite-challenging-market-backdrop-q1-earnings-beat-estimates" target="_blank" rel="noreferrer noopener">Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide</a>
The company&#8217;s growing lineup of recent launches may also help drive sales of older products over time, Vazquez says.
Why It Matters: These products alone could contribute around five percentage points to overall growth in 2025. William Blair upgraded Elanco&#8217;s rating from <a href="https://www.benzinga.com/quote/ELAN/analyst-ratings" target="_blank" rel="noreferrer noopener">Market Perform to Outperform</a>.
Recently, the European Medicines Agency&#8217;s Committee for Veterinary Medicinal Products granted a positive opinion to Elanco&#8217;s Zenrelia (ilunocitinib). The company expects approval and product supply in the market before the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45914288/elanco-receives-positive-opinion-on-zenrelia-ilunocitinib-from-eus-committee-for-veterinary-medici" rel="noreferrer noopener">end of the third quarter</a>.
The management noted that when new customers start using newer farm animal products like Bovaer and Experior—which currently face little to no competition—it can also increase demand for older products like Rumensin.
William notes that Elanco faces tough competition from big, well-funded companies that are also investing heavily in developing new products.
Competition: Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) JAK inhibitor could affect how well Elanco's drug Zenrelia performs globally. Merck's drug is expected to have fewer safety concerns.
Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) also has a strong track record of improving existing products, analysts say. That could make it harder for Elanco's new drugs to gain market share.
Price Action: ELAN stock is up 3.05% at $14.18 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens" target="_blank" rel="noreferrer noopener">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Upgrades

Movers

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

Across the recent three months, 4 analysts have shared their insights on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $176.25, a high estimate of $210.00, and a low estimate of $160.00. A 4.6% drop is evident in the current average compared to the previous average price target of $184.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1750276872_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zoetis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Andrea Alfonso</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zoetis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zoetis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Zoetis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zoetis analyst ratings.</a>
<h2>Delving into Zoetis's Background</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Zoetis's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zoetis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.37%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Zoetis's net margin is impressive, surpassing industry averages. With a net margin of 28.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zoetis's ROE excels beyond industry benchmarks, reaching 13.39%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.45%, the company showcases effective utilization of assets.
Debt Management: Zoetis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.45.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Zoetis

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Evercore ISI Group raised Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) price target from $145 to $205. Evercore ISI Group analyst Nicholas Amicucci maintained an Outperform rating. Centrus Energy shares closed at $173.03 on Tuesday. <a href="https://www.benzinga.com/quote/LEU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from $90 to $84. B of A Securities analyst Steve Byrne maintained a Buy rating. Westlake shares closed at $73.24 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised REV Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) price target from $33 to $46. Morgan Stanley analyst Angel Castillo upgraded the stock from Underweight to Equal-Weight. REV Group shares closed at $43.55 on Tuesday. <a href="https://www.benzinga.com/quote/REVG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased the price target for Darden Restaurants, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) from $215 to $235. Morgan Stanley analyst Brian Harbour maintained an Overweight rating. Darden shares closed at $224.78 on Tuesday. <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth Capital raised the price target for Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) from $92 to $116. Roth Capital analyst Boobalan Pachaiyappan reiterated a Buy rating. Verona Pharma shares closed at $92.93 on Tuesday. <a href="https://www.benzinga.com/quote/VRNA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities increased Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) price target from $52 to $64. Truist Securities analyst William Stein maintained a Hold rating. Microchip Technology shares settled at $67.69 on Tuesday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer raised Roblox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NASDAQ">RBLX</a>) price target from $80 to $125. Oppenheimer analyst Martin Yang reiterated an Outperform rating. Roblox shares closed at $101.12 on Tuesday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James increased Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $78 to $84. Raymond James analyst David Long reiterated a Strong Buy rating. Wells Fargo shares closed at $72.50 on Tuesday.  <a href="https://www.benzinga.com/quote/WFC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut the price target for Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) from $165 to $160. Stifel analyst Jonathan Block downgraded the stock from Buy to Hold. Zoetis shares settled at $161.67 on Tuesday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim increased Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) price target from $220 to $250. Guggenheim analyst John Difucci maintained a Buy rating. Oracle shares closed at $208.18 on Tuesday. <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ORCL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ORCL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18150837/image-292-1024x596.png" alt="" class="wp-image-954432" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18150837/image-292-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18150837/image-292-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18150837/image-292-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18150837/image-292.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46001244/uber-southern-company-more-on-cnbcs-final-trades">Uber, Southern Company And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo via Shutterstock

Price Target

Markets

MCHP

ORCL

RBLX

REVG

VRNA

Oracle To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

Zoetis shares are trading lower after Stifel downgraded the stock from Buy to Hold and lowered its price target from $165 to $160.

Stifel analyst Jonathan Block downgrades Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) from Buy to Hold and lowers the price target from $165 to $160.

Downgrades

Stifel Downgrades Zoetis to Hold, Lowers Price Target to $160

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.01%. Currently, Zoetis has a market capitalization of $69.84 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $3,123.56 today based on a price of $156.87 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750260611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Zoetis 10 Years Ago Would Be Worth This Much Today

Recent stock trades made by a senator could show conflicts of interest given his committee assignments and ramp up the call to ban members of Congress from being able to buy and sell stocks.
Here's a look at the recent stock trades made by Senator Markwayne Mullin (R-Okla.).
What Happened: Mullin recently bought stock in several stocks, while also selling a position in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500. The trades are shown on the <a href="https://www.benzinga.com/gov-trades/members/markwayne-mullin">Benzinga Government Trades page.</a>
According to a recent disclosure, Mullin bought the following stocks on May 13:
<ul class="wp-block-list">
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>): $15,000 to $50,000</li>
<li>Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>): $15,000 to $50,000</li>
<li>CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>): $15,000 to $50,000</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): $50,000 to $100,000</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>): $15,000 to $50,000</li>
<li>LPL Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>): $15,000 to $50,000</li>
<li>L3 Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>): $15,000 to $50,000</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>): $15,000 to $50,000</li>
<li>Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>): $15,000 to $50,000</li>
<li>Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): $15,000 to $50,000</li>
<li>Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>): $50,000 to $100,000</li>
<li>Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>): $50,000 to $100,000</li>
</ul>
In the same disclosure, Mullin also reported selling $500,000 to $1 million worth of SPDR S&amp;P 500 ETF Trust.
He reportedly bought between $285,000 and $750,000 in new stock positions, along with total transactions ranging from $785,000 to $1.75 million.
One of the most active stock traders in the Senate, Benzinga shows 325 trades worth $8.47 million, and Quiver Quant <a href="https://www.quiverquant.com/congresstrading/politician/Markwayne%20Mullin-M001190">shows </a>$15.5 million in trades from Mullin in recent years.
His net worth is listed by Quiver Quant at $65.7 million, with part of the wealth coming from selling businesses before becoming a Congressman from 2013 to 2023 and later a Senator since 2023.
The Senator's purchase of L3 Harris Technologies could raise red flags, given that it is a large defense stock and Mullin <a href="https://www.senate.gov/general/committee_assignments/assignments.htm#MullinOK">sits </a>on the Committee on Armed Services.
The purchase of oil stocks also involves Mullin, who belongs to the Subcommittee on the Department of Interior, Environment, and Related Agencies.
The Republican senator is on numerous committees and could have inside information about government policy and contracts while making his stock transactions.
Mullin denied past conflicts of interest when he owned shares of Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and was set to vote on a potential TikTok ban, which could help Meta.
Check This Out:
<ul class="wp-block-list">
<li>Lawmakers Are Making Huge Investments In 2025. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent061225">See What They&#8217;re Buying And Selling With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Mullin's latest trades come as a call to ban members of Congress from buying and selling stocks and options is gaining support.
Sen. Josh Hawley (R-Mo.)<a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act" target="_blank" rel="noreferrer noopener"> introduced the</a> Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act, based on the first letter of each of the main words. The name takes aim at Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).
Pelosi, whose husband is a frequent stock trader and venture capitalist, likely doesn&#8217;t support the bill that would limit her husband's transactions while she&#8217;s in office.
Speaker of the House Mike Johnson (R-La.), also in <a href="https://www.benzinga.com/politics/25/05/45449720/speaker-johnson-backs-congressional-stock-trading-ban-ruined-by-a-few-bad-actors">favor of a ban</a>, said there is zero tolerance for &#8220;anything resembling insider trading.&#8221;
President Donald Trump recently said he would support such a ban and that he would sign the bill if Congress passed it
"Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it," Trump told TIME.
Benzinga<a href="https://www.benzinga.com/trading-ideas/25/05/45552223/exclusive-congress-trading-ban-sees-huge-support-in-reader-poll-heres-the-percent-that-say-let-them-keep-trading-stocks"> recently polled readers</a> to see where they stand on a potential ban on Congress trading.
&#8220;Should members of Congress be allowed to buy and sell stocks, options and ETFs?&#8221; Benzinga asked.
These were the results:
<ul class="wp-block-list">
<li>They should not be allowed to trade stocks, options or ETFs:&nbsp;43%</li>
<li>They should be allowed to trade as long as they report within 24 hours:&nbsp;24%</li>
<li>They should only be allowed to trade ETFs and mutual funds:&nbsp;14%</li>
<li>They should be allowed to trade as long as they report in 45 days: 11%</li>
<li>They should only be allowed to trade stocks: 8%</li>
</ul>
The poll found that 43% of readers support an outright ban on members of Congress being able to trade stocks, options, or ETFs. Eleven percent voted that the current rules should be left alone with a 45-day disclosure window.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip">Marjorie Taylor Greene Brushes Off Stock Buying Criticism, Says Portfolio Manager &#8216;Bought The Dip&#8217;</a></li>
</ul>
Photo: Shutterstock

Politics

ADBE

AMAT

LPLA

LRCX

GOP Senator On Armed Services Committee Buys This Defense Stock In Potential Conflict Of Interest

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 2.03% on an annualized basis producing an average annual return of 12.86%. Currently, Zoetis has a market capitalization of $74.02 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $3,339.90 today based on a price of $166.26 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748383212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he doesn't like ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), adding that &#8220;<a href="https://www.benzinga.com/quote/ZIM/earnings">dividend is a sucker's play.&#8221;</a>
On the earnings front, the company posted quarterly earnings of $2.45 per share on May 19, beating the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $2.01 billion, also beating the analyst consensus estimate of $1.85 billion.
Cramer recommended not buying The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) because the stock is up too much. &#8220;A parabolic move. If I come in now, I think I am too late,&#8221; he added.
On May 6, Mosaic reported quarterly earnings of 49 cents per share, which beat the analyst consensus estimate of 45 cents per share. The company reported quarterly sales of $2.62 billion, which missed the analyst consensus estimate of $2.66 billion.
&#8220;It does seem to be dead money,&#8221; Cramer said when asked about Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>). &#8220;I don't see much happening in the veterinary or livestock market at this very moment that's going to help them.&#8221;
As per recent news, the animal health firm reported a first-quarter 2025 adjusted EPS of $1.48 on May 6, up from $1.38 a year ago and beating the consensus of $1.39.
Price Action:
<ul class="wp-block-list">
<li>ZIM shares fell 2.7% to settle at $18.85 on Tuesday.</li>
<li>Mosaic shares rose 0.5% to close at $35.53 during the session.</li>
<li>Zoetis shares fell 0.2% to settle at $163.65 on Tuesday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Media

Jim Cramer Recommends Not Buying Mosaic, Doesn't Like This Industrial Stock

In the current market session, Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) share price is at $161.01, after a 1.25% decrease. Over the past month, the stock increased by 8.79%, but over the past year, it actually fell by 5.56%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747670419_0.png" alt="Past Year Chart" />

<h3>How Does Zoetis P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Zoetis has a better P/E ratio of 29.27 than the aggregate P/E ratio of 24.46 of the Pharmaceuticals industry. Ideally, one might believe that Zoetis Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747670420_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Zoetis Inc's Price Over Earnings

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 2.07% on an annualized basis producing an average annual return of 12.73%. Currently, Zoetis has a market capitalization of $71.42 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $336.54 today based on a price of $160.43 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today

Ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Zoetis and provided 12-month price targets. The average target is $205.33, accompanied by a high estimate of $244.00 and a low estimate of $165.00. A 2.14% drop is evident in the current average compared to the previous average price target of $209.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1747083633_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Zoetis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Andrea Alfonso</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$244.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$238.00</td>
<td>$243.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zoetis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zoetis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zoetis's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zoetis analyst ratings.</a>
<h2>Discovering Zoetis: A Closer Look</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Key Indicators: Zoetis's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Zoetis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.37%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Zoetis's net margin excels beyond industry benchmarks, reaching 28.42%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zoetis's ROE excels beyond industry benchmarks, reaching 13.39%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Zoetis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.45%, the company showcases efficient use of assets and strong financial health.
Debt Management: Zoetis's debt-to-equity ratio surpasses industry norms, standing at 1.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Zoetis Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Zoetis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) short percent of float has risen 21.39% since its last report. The company recently reported that it has 9.33 million shares sold short, which is 2.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zoetis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747076431_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoetis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zoetis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zoetis's peer group average for short interest as a percentage of float is 3.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Zoetis?

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $205 to $210.

Piper Sandler Maintains Overweight on Zoetis, Raises Price Target to $210

Live On CNBC, Brenda Vingiello Announces Bought Quanta Services; Announces Sold Zoetis

UBS analyst Andrea Alfonso maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Neutral and lowers the price target from $189 to $170.

UBS Maintains Neutral on Zoetis, Lowers Price Target to $170

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of <a href="https://www.benzinga.com/topic/federal-reserve">Wednesday&#8217;s Federal Reserve meeting.</a>
In a meeting with Canadian Prime Minister Mark Carney, President Donald Trump suggested the U.S. may soon begin renegotiating the USMCA. He noted that China is eager to negotiate due to its struggling economy, driven by a lack of U.S. trade, but emphasized the talks would take place &#8220;at the right time.&#8221;
Trump kept his trade stance unclear, suggesting that while some agreements may be signed, there is no obligation to finalize any, and dismissed repeated questions about the number of deals in progress.
The S&amp;P 500 dipped 30 points, or 0.6%, to 5,610, on track for its second consecutive negative session after nine straight gains. The Nasdaq 100 dropped 0.8%, while the Russell 2000 slipped 1%.
Ten of the 11 S&amp;P 500 sectors were in the red, with utilities as the only sector in the green. The U.S. dollar fell, extending its losses for a third straight session.
Commodities saw a broad rally, with oil prices surging 3.6%, pushing WTI above $59, following <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224883/oil-soars-above-59-as-middle-east-airstrikes-jolt-markets">Israeli airstrikes in Yemen</a>. Gold also rallied, climbing 2.4% to above $3,400 per ounce amid heightened geopolitical tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reversed Monday's gains, slipping 0.4% to $94,375.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.65</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,905.06</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,796.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,983.93</td>
<td colspan="2">-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.7% to $559.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.8% to $409.01.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.9% to $481.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 1.1% to $196.68.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.2%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.4%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: 
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) up 2.70%</li>
<li>The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) down 2.31%</li>
<li>Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) down 9.95%</li>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) down 13.9%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) down 0.53%</li>
<li>Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) down 0.68%</li>
<li>The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) down 5.19%</li>
<li>Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) up 9.14%</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) down 7.37%</li>
<li>Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) down 13.6%</li>
<li>Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) up 3.61%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 13.6%</li>
<li>Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) up 2.24%</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) up 10.94%</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) down 5.67%</li>
<li>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) up 1.26%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) down 3.32%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 0.52%</li>
<li>Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 0.37%</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) down 2.88%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.77%</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) up 1.14%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) down 1.32%</li>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) up 2.02%</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) down 4.43%</li>
<li>Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) up 4.11%</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) down 1.43%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) down 3.57%</li>
<li>Expeditors International of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) down 3.67%</li>
<li>Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) up 0.55%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) down 5.56%</li>
</ul>
Stocks slated to report earnings after the close include: Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>), Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) and Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45205780/sp-500-stocks-that-defy-sell-in-may-myth-5-companies-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Photo: Gumbariya via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Mid Cap

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Global

Econ #s

Economics

ETFs

$BTC

ANET

BALL

COTY

CPAY

CTRA

SPDR Dow Jones Industrial Average ETF Trust

EXPD

FANG

JKHY

LDOS

LSCC

PLTR

RIVN

SMCI

VRTX

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?

Zoetis shares are trading lower. The company reported Q1 financial results.

Animal health firm Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">consensus of $1.39</a>.
Adjusted net income for the first quarter of 2025 was $662 million, or $1.48 per diluted share. That&#8217;s an increase of 6% and 8%, respectively, <a href="https://www.benzinga.com/pressreleases/25/05/b45217035/zoetis-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">on an organic operational basis</a>.
Adjusted net income for the first quarter of 2025 excludes the net impact of $31 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt" rel="noreferrer noopener">Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal</a>
The company reported sales of $2.22 billion, up 1% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $2.19 billion</a>.
On an organic operational&nbsp;basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024.
Revenue in the U.S. segment was $1.2 billion, an increase of 2% compared with the first quarter of 2024 and an increase of 6% on an organic operational basis.
Sales of companion animal products increased by 8%, driven by Simparica Trio, the company&#8217;s flea tick and heartworm combination product, key dermatology products Apoquel&nbsp;and Cytopoint, and monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela&nbsp;for dogs and Solensia&nbsp;for cats.
Guidance: Zoetis raised its fiscal 2025 revenues guidance from $9.225 billion &#8211; $9.375 billion to  $9.425 billion &#8211; $9.575 billion, compared to the consensus of $9.33 billion.
The company maintains an organic operational growth of 6% to 8%. It expects a reported net income of $2.630 billion—$2.68 billion, compared to <a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">prior guidance of $2.57 billion &#8211; $2.62 billion</a>.
The animal company raised its adjusted net income guidance to $2.775 billion &#8211; $2.825 billion from $2.70 billion and $2.75 billion, with organic operational growth of 6% to 8% (compared to 5% &#8211; 7% earlier).
Zoetis forecasts a reported EPS of $5.85 to $5.95 compared to prior guidance of $5.70-$5.80 and adjusted EPS of $6.20-$6.30 from between $6.00 and $6.10, compared to a consensus of $6.09.
The company says the guidance reflects foreign exchange rates as of late April and the impact of enacted tariffs.
Price Action:&nbsp;ZTS stock is down 1.11% at $156.30 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45209967/biocryst-pharmaceuticals-soars-23-in-one-session-heres-why-it-surprised-investors" target="_blank" rel="noreferrer noopener">BioCryst Pharmaceuticals Soars 23% In One Session &#8211; Here&#8217;s Why It Surprised Investors</a></li>
</ul>

Earnings

Guidance

Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) raises FY2025 GAAP EPS guidance from $5.70-$5.80 to $5.85-$5.95 vs $5.81 analyst estimate..

Zoetis Raises FY2025 GAAP EPS Guidance from $5.70-$5.80 to $5.85-$5.95 vs $5.81 Est

Press Releases

Zoetis Declares Second Quarter 2025 Dividend

Zoetis Reports Fourth Quarter and Full Year 2024 Results

Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

Zoetis to Participate in Upcoming Investor Conferences

Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

Zoetis Announces First Quarter 2025 Results

Zoetis Declares Third Quarter 2025 Dividend

Dr. Mark Stetter Elected to Zoetis Board of Directors

Zoetis Releases 2024 Sustainability Progress Update

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Stifel

Piper Sandler

Barclays

Morgan Stanley

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Zoetis

뉴스

에 대한 최신 뉴스 Zoetis (NYSE:ZTS) 주식

월요일, 12월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌